08.00 What do we really know about pedal angiosomes? When is the collateral circulation adequate to heal the foot through indirect revascularization and how do we know when we have done enough? V. Alexandrescu
	08.07 The first commandment of angioplasty for CLI: respect the “landing zone” R. Ferraresi
	08.14 Pedal angioplasty: in which cases does it help and when is it too risky? M. Fusaro
	08.21 Discussion
	08.26 Tools and options for crossing long tibial occlusions, J. Brunet
	08.33 Dedicated, self-expanding, drug eluting stent for the BTK arteries: the Stentys device and 6 month trial results, K. Deloose
	08.40 Is there a place for very distal BTK stenting? What are the options for acute PTA failure? E. Puras Malagray
	08.47 Bifurcated BTK stents: when and how to do it, G. Coppi
	08.54 Discussion
	09.00 BTK drug coated balloons will eventually solve our problem with CLI, G. Tepe
	09.08 Drug coated balloons are dangerous in CLI. How about PTA or atherectomy with bailout DES when needed? M. Bosiers
	09.16 Discussion
	09.20 What evidence do we have for an “endo first” approach to CLI? Is it good marketing or good science? P. Schneider
	09.28 Indian experience in CLI, R. Tripathi
	09.36 These are the trials that need to be done to advance CLI, M. Bosiers
	09.44 Discussion
	09.50 Panel discussion
10.45 Coffee break in the exhibition hall
	11.15 History of covered stents for small and medium size vessels, L. Inglese
	11.25 Why I prefer to use conventional stents instead of covered stents for renal artery stenosis, C. Rabbia
	11.35 Covered stents vs coiling or in combination for bail out of visceral vessels aneurysms, F. Numan
	11.45 Covered or semi covered stent for CAS. A glimpse into the future? N. Hopkins
	11.55 Choice of covered stents for chimney, parallel or sandwich procedures, M. Lachat
	12.05 Covered stents vs bare in treating CoAo or reCoAo, Z. Krajcer
	12.15 SFA & POP a. restenosis: is there a role for covered stents? P. Schneider
	12.25 Which type of neointima could we expect after covered stent deployment?
	What and how long should we anti aggregate? K. Mathias
	12.35 Discussion
	
	13.00 Lunch break
	14.00 Evidence for endovascular treatment for TASC C and D femoral lesions, K. Deloose
	14.10 CTO long recanalization: tips and tricks for crossing and re-entry, R. Ferraresi
	14.20 Retrograde accesses and possibilities for CTO recanalization, E. Ducasse
	14.30 Long stenting for CTO management, Y. Gouëffic
	14.40 Focal stenting for CTO management, P. Schneider
	14.50 DEB for CTO management, G. Tepe
	15.00 Covered stent for CTO management, F. Verzini
	15.10 DES for CTO management, P. Commeau
	15.20 Recanalization management for CTO with previous stent, S. Ronchey
	15.30 Video case of CTO management, A. Sauguet
	15.40 Discussion
18.00 Adjournment